Launched in August, HTG’s Transcriptome Panel is designed to measure approximately 20,000 mRNA targets using EdgeSeq technology.
“I believe the ability to capture [approximately] 20,000 genes from a single tissue section with the HTG Transcriptome Panel will be a game-changer,” said Amir Horowitz, PhD, assistant professor of oncological sciences at Icahn Mount Sinai.
Through the collaboration, HTG will provide in-kind laboratory services in connection with three separate clinical study cohorts focused on bladder cancer from Icahn Mount Sinai.
Leave a Reply